Sabin’s President, Dr. Peter Hotez, received the 2015 RESULTS Seeds of Hope Award on Sunday in Houston, Texas. Each year, this award honors a person in the Houston community who has made extraordinary contributions towards improving health, education or microfinance — the three pillars of RESULTS advocacy. This year’s award honored advances in Child and Maternal Health.

Sabin PDP, King Saud University Sign Project Agreement to Build Vaccine Research and Development Capacity in Saudi Arabia

WASHINGTON, D.C. — November 16, 2015 — The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today signed a project agreement with King Saud University to build vaccine research and development capacity in the Middle East and North Africa (MENA) region and advance the establishment of a vaccine research institute in Saudi Arabia.

My role as a U.S. Science Envoy in 2015 has focused on a worrisome trend that became especially obvious following the emergence of the Ebola virus infection in West Africa last year.

During the month of October, END7 student supporters are celebrating NTD Success Stories — spreading the exciting news that many countries around the world have already made incredible progress towards the control and elimination of some NTDs. In recent weeks, there have been many new successes to celebrate.

New Partnership with India Aims to Build Vaccine Manufacturing Network for Hookworm, Other Diseases

WASHINGTON, D.C., BANGALORE, AMSTERDAM — October 14, 2015 — The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs). The European Union, through its EuropeAid program, recently awarded a five-year grant of €333,000 to AIGHD to establish this EU-India partnership.

The initial research for the Ebola vaccine was published in 2003, where it sat for more than a decade waiting for a vaccine manufacturer to invest in licensing and development. Only after the 2014 outbreak began did the U.S.

Pages